As a patient living with metastatic breast cancer for 7 years it is imperative that the patient perspective is a part of ALL areas of breast cancer from research to treatment. Thank you Lesley Glenn for representing the #MBC community. #SABCS2023#bcsm#Shareddescionmaking
Today’s MARP pair spotlight is researcher Hannah Carter from @TAMUGENE and advocate Katie Edick @KatieEdick. #BCAM
Read their blog post here! https://t.co/3CxxQr8pJr
“I'm alive today because patients in the 90s participated in #clinicaltrials for Herceptin.” MBCA patient advocate member Christine Hodgdon reimagines clinical trials: decentralization, fewer exclusions and broader participation.
https://t.co/62BdH7QNiK
#bcam
“The voices of people living with this disease should be at the table.” Kelly Shanahan, MBCA patient advocate member, encourages #clinicaltrials participation from patients and more inclusivity from the medical industry.
https://t.co/ngaR2iHHfJ
#bcam
"There were no options to treat my type of #breastcancer because of lack of equity in #clinicaltrials." Maimah Karmo, advocate and CEO of @tigerlilycares, explains how equity in access to clinical trials can save lives.
https://t.co/rsiZtvJpBm
#bcam
Trail blazing! Asked my onc about #phesgo from @genentech. 5 min injection vs. the 1.5+ hours in an infusion chair. Never given @SparrowHealth, next pharmacy board. Will it be approved? This is why I went to #SABCS2022. Learning cutting edge research, new drugs and technology.
Sometimes life is serendipitous. At the airport, I was fortunate to sit next to @doctor_nova, an amazing oncologist, studying HER2+ BC (I'm triple posistive). So much hope for those of us living with MBC. Thank you for answering my questions! #SABCS22#MBC#researchnotribbons
This is what those of us living with MBC want too - live longer AND live better. It should never be a choice between the two. We and the people who love us deserve both. #SABCS22#bcsm
And why should we care? Because a ton of people who are classified as HER2- have 1+ or 2+ expression and could benefit from TDxD and maybe other HER2 targeted therapies. #HER2low#SABCS22#bcsm
#SABCS22 PSA: Don’t miss the “Living with Metastatic Breast Cancer” session at 10am CT in Stars at Night 3/4!
@christeeny513 & @faceofstage4 will provide the patient perspective, and will be joined by @fumikochino, @AbbeyKaler, @BlaesAnneMD, @Tara_KaufmannMD.
Can we cure De novo HER2+ MBC? Yes @DrEricWiner
but the questions are:
1- which subset of pts?
2- what is the optimal tx?
3- any imaging or biomarkers to guide therapy discontinuation?
4- Role of local Tx to mets site?
#ESMOBreast21@OncoAlert#bcsm
So - now that everyone spent 31 days becoming “aware” of #breastcancer, can we agree the orientation period is over?
Breast Cancer doesnt magically disappear November 1st. We STILL NEED ACTION! Research & Policy changes have to continue the other 334 days of the year.
#mbc#bcsm